Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Shares of Johnson & Johnson are up 0.86% at $271.49. The company is worth $654.25B, number 22 out of 300 on our list.
Over the past 52 weeks it has traded between $175.84 and $281.07, so it sits 3.4% below the top of that range. Holders are ahead 57.1% over twelve months, and up 13.2% across the last three months.
On the chart it holds above both the 50-day ($263.37) and 200-day ($237.55) moving averages; RSI is 57, and the last 30 sessions moved at roughly 19% annualized volatility.
For the quarter ended Jun 2026 it reported $25.31B in revenue, up 6.6% from a year earlier, with $5.53B of net profit (a 21.5% margin).
Buyers are paying 31.5 times trailing earnings, 44% above its five-year average of 21.9. The median for its industry group is 20.4.
18 analysts follow the stock and the average call is "buy". The mean target, $286.61, sits 5.6% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Johnson & Johnson makes prescription drugs and medical devices, after spinning off its consumer health business as Kenvue.
What tends to move it. Oncology and immunology drug sales, talc litigation and orthopedic device recovery drive the shares. It is a long-time dividend raiser.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +0.8% | Bullish |
| Price vs 50-day average | +3.1% | Bullish |
| Price vs 200-day average | +14.3% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 57.0 | Bullish |
| MACD (12,26,9) | 1.59 | Bearish |
| Bollinger band position | 65% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 2:00 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 88th percentile, 5-year average 21.9x
#2098 of 2977 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 98th percentile, 5-year average 5.8x
#4661 of 5304 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 98th percentile, 5-year average 4.7x
#4106 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: +$36.10M (10 inflow days, 10 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 6.4% a year.
$271.49 is the latest print for JNJ, a move of +0.86% against yesterday's close of $269.17. Today's low and high so far: $269.01 and $275.23.
Equity value comes to $654.25B at the current price. By that measure it is number 22 of the 300 names in our coverage.
Buyers pay 31.5 times the last twelve months of profit (EPS $11.03). Averaged over five years the multiple has been 21.9, and today's level ranks in the 88th percentile of its own history.
The year's floor is $175.84 and the ceiling $281.07. Shares are 3.4% away from that ceiling.
It does. Payouts over the past twelve months work out to a 1.93% yield; the latest ex-dividend date was August 25, 2026.
Of 18 analysts, 78% say buy, 22% hold and 0% sell. Price targets average $286.61, with the most cautious at $260.00 and the most optimistic at $320.00.
Johnson & Johnson makes prescription drugs and medical devices, after spinning off its consumer health business as Kenvue.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.